EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

mTOR-mediated p62/SQSTM1 stabilization confers a robust survival mechanism for ovarian cancer

Tomohiro Tamura, Shimpei Nagai, Kenta Masuda, Keiyo Imaeda, Eiji Sugihara, Juntaro Yamasaki, Miho Kawaida, Yuji Otsuki, Kentaro Suina, Hiroyuki Nobusue, Tomoko Akahane, Tatsuyuki Chiyoda und 11 weitere

Cancer Letters · 2025-04 · 616 · 217565

DOI: 10.1016/j.canlet.2025.217565 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2025-04. Verfasst von Tomohiro Tamura und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan; Department of Extended Intelligence for Medicine, The Ishi…. Hauptthemen laut MEDLINE: TOR Serine-Threonine Kinases, Ovarian Neoplasms, Sequestosome-1 Protein, Cystadenocarcinoma, Serous. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Kobayashi Foundation for Cancer Research, AMED.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over 50 % of patients with high-grade serous carcinoma (HGSC) are homologous recombination proficient, making them refractory to platinum-based drugs and poly (ADP-ribose) polymerase (PARP) inhibitors. These patients often develop progressive resistance within 6 months after primary treatment and tend to die early, thus new therapies are urgently needed. In this study, we comprehensively investigated this tumor type by leveraging a combination of machine learning analysis of a large published dataset and newly developed genetically engineered HGSC organoid models from murine fallopian tubes. Aberrant activation of RAS/PI3K signaling was a signature of poor prognosis in BRCA1/2 wild-type ovarian cancer, and mTOR-induced elevated p62 expression was a robust marker of chemotherapy-induced mTOR-p62-NRF2 signal activation. mTOR inhibition with everolimus decreased p62 and enhanced sensitivity to conventional chemotherapy, indicating that p62 serves as an important biomarker for therapeutic intervention. Combination therapy with conventional chemotherapy and mTOR inhibitors is a promising therapeutic strategy for refractory HGSC, with p62 as a biomarker.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TOR Serine-Threonine KinasesOvarian NeoplasmsSequestosome-1 ProteinCystadenocarcinoma, SerousFemaleHumansAnimalsMiceSignal TransductionMTOR InhibitorsCell Line, TumorDrug Resistance, Neoplasm

Stichwörter der Autor:innen

BRCA1/2 wild typeOvarian cancermTOR inhibitorp62/SQSTM1

Substanzen

TOR Serine-Threonine KinasesSequestosome-1 ProteinMTOR protein, humanSQSTM1 protein, humanMTOR Inhibitors

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan; Department of Extended Intelligence for Medicine, The Ishii-Ishibashi Laboratory, Keio University School of Medicine, Tokyo, Jap…
  • Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan.
  • Department of Obstetrics and Gynecology, Keio University School of Medicine, Tokyo, Japan. Electronic address: ma-su-ken.a2@keio.jp.
  • Division of Gene Regulation, Oncology Innovation Center, Fujita Health University, Toyoake, Japan.
  • Division of Diagnostic Pathology, Keio University Hospital, Tokyo, Japan.
  • Department of Neurosurgery, Yale School of Medicine, New Haven, CT, USA; Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Förderung

  • Japan Society for the Promotion of Science
  • Kobayashi Foundation for Cancer Research
  • AMED
  • Japan Science and Technology Agency Moonshot Research and Development Program

Zitieren

APA

Tamura, T., Nagai, S., Masuda, K., Imaeda, K., Sugihara, E., Yamasaki, J., Kawaida, M., Otsuki, Y., Suina, K., Nobusue, H., Akahane, T., Chiyoda, T., Kisu, I., Kobayashi, Y., Banno, K., Sakurada, K., Okita, H., Yamaguchi, R., Ahmed, A. A., …, & Nagano, O. (2025). mTOR-mediated p62/SQSTM1 stabilization confers a robust survival mechanism for ovarian cancer. Cancer Letters, 616, 217565. https://doi.org/10.1016/j.canlet.2025.217565

Vancouver

Tamura T, Nagai S, Masuda K, Imaeda K, Sugihara E, Yamasaki J, et al. mTOR-mediated p62/SQSTM1 stabilization confers a robust survival mechanism for ovarian cancer. Cancer Letters. 2025;616:217565. doi:10.1016/j.canlet.2025.217565

BibTeX
@article{Tamura2025,
  author = {Tamura, Tomohiro and Nagai, Shimpei and Masuda, Kenta and Imaeda, Keiyo and Sugihara, Eiji and Yamasaki, Juntaro and Kawaida, Miho and Otsuki, Yuji and Suina, Kentaro and Nobusue, Hiroyuki and Akahane, Tomoko and Chiyoda, Tatsuyuki and Kisu, Iori and Kobayashi, Yusuke and Banno, Kouji and Sakurada, Kazuhiro and Okita, Hajime and Yamaguchi, Rui and Ahmed, Ahmed Ashour and Yamagami, Wataru and Saya, Hideyuki and Aoki, Daisuke and Nagano, Osamu},
  title = {mTOR-mediated p62/SQSTM1 stabilization confers a robust survival mechanism for ovarian cancer},
  journal = {Cancer Letters},
  year = {2025},
  volume = {616},
  pages = {217565},
  doi = {10.1016/j.canlet.2025.217565}
}
Kostenlos starten →